A week post Bayer’s announcement on the withdrawal of Essure, its contraceptive implant from the market by this year-end due to inadequate sales, its clinical safety is questioned as consumer and legal stress builds up concerning complaints of extreme fatigue, pain and bleeding.
Novartis has renewed its memorandum of understanding with the World Health Organization (WHO) to lengthen its drug donation for Egaten® (triclabendazole) to 2022 and continues its war against liver fluke. WHO lists Egaten as the only medicine for fascioliasis and also includes it in the Model List of Essential Medicines.
The opening of a new Biomedical Blockchain Research Center was announced by the Icahn School of Medicine at Mount Sinai and the Institute for Next Generation Healthcare which aims to solve healthcare and medical science issues with new technologies and data.
In a recent launch, Novartis’ Galaxies of Hope neuroendocrine tumor app received an additional bump from Apple. The “Featured App” status in the first week itself helped in receiving positive reviews and downloads for the community-building app.
Bayer announced on last Friday that it would stop the sales of its Essure birth control system in the United States by the end of this year due to a steady decline in its sales making the product no longer justifiable. Bayer insisted that its decision to discontinue Essure sales is only for business reasons and not for any safety or efficacy concerns.
LabCorp, the mammoth medical investigations company, is still recuperating from a major ransomware attack and, almost a week later, won’t reveal how the hackers got entry nor the number of servers that were hit.
Pharmaceutical giant AstraZeneca and integrated health services provider Geisinger are partnering to create an app suite, which by connecting to electronic health records (EHR) aims to upgrade asthma care.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.